Company profile: Tobira Therapeutics
1.1 - Company Overview
Company description
- Provider of research, discovery, acquisition, development, and commercialization of antiviral compounds for treating life-threatening and life-altering infectious diseases, including HIV/AIDS and hepatitis; develops TBR-652 and TBR-220 antagonists.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tobira Therapeutics
Sellas Life Sciences
HQ: Bermuda
Website
- Description: Provider of late-stage cancer immunotherapies, developing Galinpepimut-S (GPS), a WT1-targeting synthetic heteroclitic epitope immunotherapeutic for various cancers to prevent relapses and potentially improve survival, and SLS009, a highly selective small molecule CDK9 inhibitor for development and commercialization worldwide outside the Greater China Region.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sellas Life Sciences company profile →
ImCheck Therapeutics
HQ: France
Website
- Description: Provider of immunomodulatory antibody therapies and discovery services targeting cancer and immune-related diseases, including BTN3A monoclonal antibodies that modulate γ9δ2/γ9Vδ2 T cells: ICT01 to activate against advanced solid tumors; ICT41 to activate for viral, bacterial, and parasitic infections; and ICT21 to antagonize dysfunctional activation in autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImCheck Therapeutics company profile →
Flexus BioSciences
HQ: United States
Website
- Description: Provider of novel anti-cancer therapeutics created, developed, and commercialized through an innovative application of unexploited insights in immunology; privately-held biopharmaceutical company founded in 2013 and headquartered in San Carlos, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Flexus BioSciences company profile →
Palleon Pharmaceuticals
HQ: United States
Website
- Description: Provider of glycoimmune checkpoint inhibitors to treat cancer, including E-602, a bi-sialidase fusion protein in Phase 1/2 trials that degrades immunosuppressive sialoglycans to restore antitumor immunity; the EAGLE platform of engineered human sialidases to strip sialic acid from cancer and immune cells; HYDRA immunohistochemistry technology to quantify sialoglycan density; and autoimmune disease R&D programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Palleon Pharmaceuticals company profile →
Cangene
HQ: United States
Website
- Description: Provider of immune therapeutics through fully integrated development and manufacturing, with a solid track record of developing and commercializing plasma-derived products that address multiple therapeutic areas; first drug WinRho SDF has been commercially available since 1980.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cangene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tobira Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tobira Therapeutics
2.2 - Growth funds investing in similar companies to Tobira Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tobira Therapeutics
4.2 - Public trading comparable groups for Tobira Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →